GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Caribou Biosciences Inc (NAS:CRBU) » Definitions » 3-Year Revenue Growth Rate

CRBU (Caribou Biosciences) 3-Year Revenue Growth Rate : 1.50% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Caribou Biosciences 3-Year Revenue Growth Rate?

Caribou Biosciences's Revenue per Share for the three months ended in Sep. 2024 was $0.02.

During the past 12 months, Caribou Biosciences's average Revenue per Share Growth Rate was -72.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was 1.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 5 years, the highest 3-Year average Revenue per Share Growth Rate of Caribou Biosciences was 2.90% per year. The lowest was 1.50% per year. And the median was 2.20% per year.

Competitive Comparison of Caribou Biosciences's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Caribou Biosciences's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Caribou Biosciences's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Caribou Biosciences's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Caribou Biosciences's 3-Year Revenue Growth Rate falls into.


Caribou Biosciences 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Caribou Biosciences  (NAS:CRBU) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Caribou Biosciences 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Caribou Biosciences's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Caribou Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Caribou Biosciences Inc (NAS:CRBU) » Definitions » 3-Year Revenue Growth Rate
Comparable Companies
MGNX CHRS TERN ICVX MLYS SPRY ERAS URGN ITOS AGEN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
2929 7th Street, Suite 105, Berkeley, CA, USA, 94710
Website
https://www.cariboubio.com
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
Executives
Syed Ali-aamir Rizvi officer: Chief Medical Officer C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Ryan Fischesser officer: See Remarks CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Steven Kanner officer: See Remarks CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
David Lee Johnson director C/O GLOBAL BLOOD THERAPEUTICS, 171 OYSTER POINT BLVD, STE. 300, SAN FRANCISCO CA 94080
Barbara G Mcclung officer: See Remarks CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Ruhi Ahmad Khan officer: Chief Business Officer C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Dara Richardson-heron director C/O CARIBOU BIOSCIENCES, INC., 29, BERKELEY CA 94710
Ran Zheng director 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Nancy Whiting director 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Fmr Llc 10 percent owner, other: See Remark 1 245 SUMMER STREET, BOSTON MA 02210
Natalie Sacks director C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Scott Braunstein director C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Rachel E. Haurwitz director, officer: See Remarks C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Andrew Guggenhime director C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Jason O'byrne officer: See Remarks CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710